RED CELL THERAPEUTICS
Live / Registered — Registered (as of 19 Oct 2021)
What this means for you
Registered since 19 Oct 2021. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88807844
- Registration number
- 6532454
- Mark type
- Stylized text
- Filed
- 24 Feb 2020
- Registered
- 19 Oct 2021
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 005 — Pharmaceuticals: Cells for medical or clinical use for the treatment of a variety of human diseases and conditions, namely, cancer, inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, genetic diseases and disorders, infectious diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, hematological diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders; pharmaceutical preparations of engineered erythroid cells for medical or clinical use for the treatment of a variety of human diseases and conditions, namely, cancer, inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, genetic diseases and disorders, infectious diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, hematological diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders; engineered erythroid cells for medical or clinical use for the treatment of a variety of human diseases and conditions, namely, cancer, inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, genetic diseases and disorders, infectious diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, hematological diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders; none of the foregoing used as vitamin-mineral supplements or for animals
Owner
- Rubius Therapeutics, Inc., Cambridge, MA, US
- Rubius Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 19 Oct 2021 — REGISTERED-SUPPLEMENTAL REGISTER
- 15 Sept 2021 — LAW OFFICE PUBLICATION REVIEW COMPLETED
- 07 Sept 2021 — APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
- 07 Sept 2021 — EXAMINER'S AMENDMENT ENTERED
- 07 Sept 2021 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 07 Sept 2021 — EXAMINERS AMENDMENT E-MAILED
- 07 Sept 2021 — EXAMINERS AMENDMENT -WRITTEN
- 21 Jul 2021 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 20 Jul 2021 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 20 Jul 2021 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 09 Feb 2021 — NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
- 06 Feb 2021 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 06 Feb 2021 — NON-FINAL ACTION E-MAILED
- 06 Feb 2021 — NON-FINAL ACTION WRITTEN
- 06 Feb 2021 — USE AMENDMENT ACCEPTED